Münchner Leukämie Labor GmbH

What Münchner Leukämie Labor GmbH does

Münchner Leukämie Labor GmbH (MLL) is a Munich-headquartered, founder-owned specialty diagnostic laboratory founded in 2005 by Prof. Dr. Claudia Haferlach, Prof. Dr. Torsten Haferlach, and Prof. Dr. Wolfgang Kern, operating as one of the world's largest dedicated leukemia and lymphoma laboratories. MLL serves hematologists, oncologists, pathologists, hospitals, and medical practices (primarily in Germany with a claimed global footprint) that submit patient bone marrow and peripheral blood samples for integrated leukemia and lymphoma diagnostics. The laboratory is housed in a 9,114 sqm facility equipped with 1,143+ instruments and operates under ISO 9001, ISO 14001, DAkkS, CAP, and Illumina Propel certifications maintained since 2009.

MLL's core technical offering is the integration of six diagnostic methodologies — cytomorphology, chromosome analysis (karyotyping), FISH, molecular genetics (NGS, PCR, digital PCR, fragment analysis), immunophenotyping (multiparametric flow cytometry), and AI-supported bioinformatics — into a single facility producing consolidated diagnostic reports. Notable technical capabilities include amplicon deep sequencing and targeted enrichment NGS panels covering several hundred genes with 1–3% sensitivity, ddPCR-based mutation detection at 0.005–0.05%, and patient-specific MRD monitoring via V-(D)-J rearrangement quantification at 0.01–0.001% sensitivity. The lab also provides automated DNA/RNA extraction (96 samples in parallel) and chimera analysis via STR polymorphism for post-transplant monitoring.

MLL generates revenue primarily through per-test transaction fees billed to submitting physicians and institutions (statutory insurance, private insurance, and various German public/health insurance schemes) and through a Pharma Services line offering clinical research support from study design through post-launch companion diagnostics. Distribution is exclusively direct: samples are shipped using MLL-provided UN 3373-certified materials, diagnostic requests are placed via a digital AIS-integrated Order-Entry Portal or a web-based follow-up ordering system, and results are delivered through the MLL Befundportal. The company operates with three affiliated entities — MLL MVZ GmbH (outpatient medical care center), MLL Dx GmbH, and MLLi GmbH — and has co-founded the Genomnetzwerk Hämatologie with two German Comprehensive Cancer Centers to advance personalized medicine in hematology.

Name

Münchner Leukämie Labor GmbH

Legal name

MLL Münchner Leukämielabor GmbH

Website

https://mll.com

Company type

Private

Founded year

2005

Operating status

Operating

Short description

Munich-headquartered specialty diagnostic laboratory providing integrated leukemia and lymphoma diagnostics — combining cytomorphology, cytogenetics, FISH, molecular genetics, immunophenotyping, and AI-supported bioinformatics — to hospitals and medical practices worldwide through direct sample submission.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF)

Keywords

• Leukemia diagnostics
• Cytogenetic analysis
• Molecular genetics
• Flow cytometry
• Bioinformatics services

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Diagnostic Laboratory Services: MLL generates revenue by providing comprehensive leukemia and lymphoma diagnostic services to hospitals, hematology practices, oncologists, and physicians. Samples (bone marrow, peripheral blood) are submitted by medical professionals and diagnostic reports are returned. Revenue is derived from billed diagnostic analyses performed on submitted patient specimens.
2. Pharma / Clinical Research Services: MLL supports clinical research from study design through post-launch diagnostics for pharmaceutical companies, providing companion diagnostics and clinical trial support services.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

MLL is a specialized medical diagnostic laboratory that performs comprehensive leukemia and lymphoma diagnostics by combining six integrated methodologies — cytomorphology, chromosome analysis, FISH, molecular genetics, immunophenotyping, and bioinformatics — on patient bone marrow and peripheral blood samples submitted by medical professionals. The lab delivers integrated diagnostic reports, supports clinical trials and pharma research, provides web-based big-data tools for variant interpretation, and operates digital portals for order entry and result retrieval.

Product overview

MLL (Münchner Leukämie Labor GmbH) operates as a medical diagnostic laboratory specializing in comprehensive diagnostics for leukemias and lymphomas. The company offers an integrated diagnostic service combining six core methodological pillars: Cytomorphology, Chromosome Analysis (karyotyping), Fluorescence in Situ Hybridization (FISH), Molecular Genetics (including NGS), Immunophenotyping, and Bioinformatics. MLL's diagnostic portfolio is delivered through a unified facility that guarantees comprehensive and prompt diagnosis through steady interdepartmental information flow. Beyond core diagnostics, MLL provides Big Data tools (web-based variant interpretation platforms), Pharma Services (clinical research support), and Research collaborations. The company operates digital portals for Order-Entry (electronic diagnostic requests) and Diagnostic Reports (online result viewing), supporting integration with customer hospital/clinic information systems.

Differentiator

Problem solved

Functional benefit

Products and services

• Diagnostik (Comprehensive Leukemia and Lymphoma Diagnostics)

Quantifiable outcome

• Processing of hundreds of millions of base pairs of sequence information per patient with coverage >400-2000x, enabling detection of small clone mutations
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Comprehensive Cancer Center Klinikum rechts der Isar TUMcoreStrategic or Co-development PartnerMLL founded the Genomnetzwerk Hämatologie (Genome Network Hematology) together with the Comprehensive Cancer Center Klinikum rechts der Isar TUM and Comprehensive Cancer Center Mainfranken/Universitätsklinikum Würzburg. The network aims to build cutting-edge patient care that unites research and practice, creating a feedback loop that generates new insights and continuously improves patient care, advancing personalized medicine in hematology.
• Comprehensive Cancer Center Mainfranken / Universitätsklinikum WürzburgcoreStrategic or Co-development PartnerMLL founded the Genomnetzwerk Hämatologie (Genome Network Hematology) together with the Comprehensive Cancer Center Mainfranken/Universitätsklinikum Würzburg and the Comprehensive Cancer Center Klinikum rechts der Isar TUM. The network aims to build cutting-edge patient care that unites research and practice, creating a feedback loop that generates new insights and continuously improves patient care, advancing personalized medicine in hematology.
• MLL MVZ GmbH (Medical Care Center)coreOthersMLL MVZ GmbH is the affiliated medical care center (Medizinisches Versorgungszentrum) operated by the MLL founders. It provides outpatient hematology and oncology care and is co-located/affiliated with the MLL diagnostic laboratory, enabling close integration between diagnostics and patient care.
• MLL Dx GmbHcoreOthersMLL Dx GmbH is listed as a jointly responsible party with MLL GmbH for the processing of personal data in the context of medical diagnostics and scientific research, indicating a shared operational and data governance structure within the MLL group of companies.
• MLLi GmbHminorOthersMLLi GmbH is listed as a jointly responsible party alongside MLL Dx GmbH for the processing of personal data in the context of medical diagnostics and scientific research, as stated in MLL's privacy policy.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• NeoGenomics: Specialty oncology/hematology reference laboratory providing molecular, FISH, flow cytometry, and cytogenetic testing for leukemia/lymphoma. Highly comparable in scope (NGS panels, MRD monitoring, cytogenetics), though larger and US-focused.
• Foundation Medicine: Roche-owned molecular diagnostics lab focused on comprehensive genomic profiling for oncology. Directly comparable to MLL's NGS-based, integrated-report model for hematologic malignancies, though it spans solid tumors as well.
• Caris Life Sciences: Molecular diagnostics and multi-omics profiling company serving oncologists, including hematologic cancers. Comparable in molecular testing depth, bioinformatics, and pharma/biopharma partnerships.

Broad incumbents

• Eurofins Scientific: One of the largest global lab-testing networks with a strong European footprint across clinical diagnostics and genomic services. Overlaps with MLL in molecular diagnostics and reference lab operations, but operates across many specialties.
• ARUP Laboratories: Major US academic medical center-affiliated reference lab offering esoteric and molecular diagnostics. Comparable in serving complex hematology/oncology workups with integrated reports and academic-grade expertise.
• Quest Diagnostics: One of the largest US clinical laboratory networks with extensive specialty hematology/oncology testing and reference lab services. Broader menu than MLL but overlaps materially in molecular and flow-based diagnostics.
• Laboratory Corporation of America (LabCorp): Large US-based clinical lab network with specialty oncology and hematology divisions. Comparable via its integrated diagnostics for cancer and pharma services; less specialist depth than MLL.

Regional players

• Synlab: Major European clinical diagnostics network headquartered in Germany, providing routine and specialty testing including oncology and genetics. Most direct regional comparator to MLL for German and EU send-out volume.

Emerging players

• Guardant Health: Specialty molecular diagnostics company focused on liquid biopsy and NGS-based oncology testing. Comparable NGS-based, bioinformatics-heavy approach; partial overlap with MLL's hematologic molecular franchise.
• Invitae (now part of Labcorp): Genetic testing company with oncology and hematology panels. Related in molecular diagnostics and bioinformatics-driven interpretation, though broader in hereditary genetics than MLL's somatic hematology focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/leukaemielabor
• Facebookde-de.facebook.com/muenchnerleukaemielabor
• LinkedInlinkedin.com/company/mll-muenchner-leukaemielabor
• Instagraminstagram.com/muenchnerleukaemielabor

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Münchner Leukämie Labor GmbH